Home >
News >
#ESHMM2022 PROGRAMME HIGHLIGHT: DEBATE ON ARTIFICIAL INTELLIGENCE IN MYELOMA
#ESHMM2022 PROGRAMME HIGHLIGHT: DEBATE ON ARTIFICIAL INTELLIGENCE IN MYELOMA
August 03, 2022
6th Translational Research Conference
MULTIPLE MYELOMA
October 7-9, 2022
Mandelieu-La Napoule, France
#ESHMM2022
Chairs: Maria-Victoria Mateos (Salamanca), Philippe Moreau (Nantes),
Vincent Rajkumar (Rochester)
REGISTER NOW
and join us in Mandelieu-La Napoule, France
for what we expect to be a great debate!
About the Conference:
An outstanding faculty of distinguished global experts will present the most recent advances and new perspectives in the field of
Multiple Myeloma and plasma disorders, from pathophysiology to diagnosis and therapy, including current challenges and new perspectives.
The plenary conference programme is designed to place emphasis on leading-edge basic and clinical research. The presentation of unpublished data is encouraged. Ample time is deliberately provided for in-depth scientific discussion and interaction. Registered participants will further benefit from a variety of opportunities for informal scientific interaction with the world’s leading experts in the field, including during small Meet the Expert sessions and Mentored Posters Walks.
Registered participants are invited to submit their Biology and Clinical abstracts. Selected abstracts will be presented as brief oral communications or posters.
Conference main topics:
• Smoldering Myeloma
• Diagnosis of Multiple Myeloma
• Frontline therapy in patients not eligible for autologous stem cell transplantation
• Frontline therapy in patients eligible for autologous stem cell transplantation
• MRD and the Microenvironment
• Relapsed Multiple Myeloma
• The Future: Recent Clinical Trials in Relapse
• Data Management Issues
• Plasma Cell Disorder
Learning objectives:
• Update on the pathophysiology of myeloma and how the disease is evolving from MGUS and SMM
• Update on the diagnostic criteria and the use of new assessments in the diagnostic process
• Treatment of young myeloma patients
• Treatment of elderly and frail myeloma patients
• Optimal sequencing at the relapse
• To know what is the role of new immunotherapic approaches and how will they fit in the landscape
• Role of novel drugs under development
• Latest updates in other plasma cell disorders beyond myeloma
The programme will include:
Plenary Sessions - Panel Discussions
Simultaneous Meet the Expert Sessions
Poster Walks - Brief Oral Communications
For more information, click here!
To meet the faculty, click here!
With the support of*:
Premium Conference Partner
*******
Diamond Conference Partner
*******
Emerald Conference Partner
*******
Ruby Conference Partner
*******
*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.